INTENSITY THERAPEUTICS, INC. - 8-K Filing
Intensity Therapeutics reported Q1 2026 financial results with a net loss of $2.4 million, down from $3.3 million in the same period in 2025, driven by reduced INVINCIBLE-3 Study costs and lower R&D expenses. The company held $10.2 million in cash and cash equivalents as of March 31, 2026. Preliminary data from the INVINCIBLE-4 Study showed 71.4% of patients receiving INT230-6 achieved a pathological complete response, compared to 33% in the standard of care group, with fewer grade 3+ adverse events. Enrollment in the INVINCIBLE-4 Study is set to resume in Q2 2026, and limited enrollment in th... (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $INTS